Hikma Pharmaceuticals (LON:HIK) Shares Down 0.1% – Time to Sell?

Shares of Hikma Pharmaceuticals PLC (LON:HIK) dropped 0.1% on Thursday . The stock traded as low as GBX 1,614 and last traded at GBX 1,652. Approximately 833,808 shares were traded during mid-day trading, a decline of 88% from the average daily volume of 6,893,593 shares. The stock had previously closed at GBX 1,653.

Hikma Pharmaceuticals News Summary

Here are the key news stories impacting Hikma Pharmaceuticals this week:

• Positive Sentiment: Group revenue rose 7% to $3.349 billion for 2025, a top‑line beat that supports underlying business momentum. Jordan: Hikma posts 7% revenue rise at $3.349bln in 2025
• Positive Sentiment: The company reported group profit/EBITDA strength and announced a share buyback, which is shareholder‑friendly and can support EPS. Hikma delivers Group revenue and profit growth and announces share buyback and leadership changes
• Neutral Sentiment: Management changes: the company has named its chair as chief executive — a material governance move that investors will watch for execution risk and strategic continuity. Hikma names chair chief executive
• Neutral Sentiment: Full‑year earnings call highlighted solid EBITDA and operational points, but commentary on margins and near‑term trends was cautious. Hikma Pharmaceuticals PLC (HKMPF) Full Year 2025 Earnings Call Highlights: Strong EBITDA …
• Negative Sentiment: Management warned of slower growth and cut guidance for the outlook; that guidance revision is cited as the primary reason for the sharp share price decline. Hikma’s shares plummet after guidance cut
• Negative Sentiment: Analysts and media flagged a margin warning tied to 2026 expectations — one report notes the stock fell ~17% on margin concerns despite results being broadly in line. Hikma posts 2025 results in line; stock down 17% on margin warning
• Negative Sentiment: Market commentary highlights a gloomy near‑term outlook and the stock’s immediate underperformance versus peers, reinforcing the negative market reaction. Hikma Pharmaceuticals falls Thursday, underperforms market

Analysts Set New Price Targets

HIK has been the subject of a number of analyst reports. JPMorgan Chase & Co. decreased their price objective on Hikma Pharmaceuticals from GBX 2,500 to GBX 2,400 and set an “overweight” rating for the company in a research note on Friday, November 7th. Berenberg Bank reissued a “buy” rating and set a GBX 2,300 target price on shares of Hikma Pharmaceuticals in a research report on Thursday, January 22nd. Deutsche Bank Aktiengesellschaft lowered their target price on shares of Hikma Pharmaceuticals from GBX 2,500 to GBX 2,400 and set a “buy” rating for the company in a research note on Friday, January 9th. Jefferies Financial Group reiterated a “buy” rating and set a GBX 2,360 price objective on shares of Hikma Pharmaceuticals in a report on Friday, November 7th. Finally, Peel Hunt reiterated a “buy” rating and issued a GBX 2,170 price target on shares of Hikma Pharmaceuticals in a research note on Friday, November 7th. Five analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Hikma Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of GBX 2,326.

Hikma Pharmaceuticals Stock Performance

The firm’s fifty day simple moving average is GBX 1,554.51 and its 200 day simple moving average is GBX 1,642.05. The company has a market capitalization of £2.91 billion, a PE ratio of 7.87, a price-to-earnings-growth ratio of 2.38 and a beta of 0.41. The company has a debt-to-equity ratio of 55.82, a current ratio of 1.66 and a quick ratio of 1.27.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 800+ (as of Feb 2025) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.